JPWO2022186282A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022186282A5
JPWO2022186282A5 JP2023503916A JP2023503916A JPWO2022186282A5 JP WO2022186282 A5 JPWO2022186282 A5 JP WO2022186282A5 JP 2023503916 A JP2023503916 A JP 2023503916A JP 2023503916 A JP2023503916 A JP 2023503916A JP WO2022186282 A5 JPWO2022186282 A5 JP WO2022186282A5
Authority
JP
Japan
Prior art keywords
agent according
nucleic acid
viral vector
diabetes
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023503916A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022186282A1 (cg-RX-API-DMAC7.html
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2022/008898 external-priority patent/WO2022186282A1/ja
Publication of JPWO2022186282A1 publication Critical patent/JPWO2022186282A1/ja
Publication of JPWO2022186282A5 publication Critical patent/JPWO2022186282A5/ja
Pending legal-status Critical Current

Links

JP2023503916A 2021-03-03 2022-03-02 Pending JPWO2022186282A1 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021033714 2021-03-03
JP2021145796 2021-09-07
PCT/JP2022/008898 WO2022186282A1 (ja) 2021-03-03 2022-03-02 糖尿病に対するhb-egf遺伝子治療

Publications (2)

Publication Number Publication Date
JPWO2022186282A1 JPWO2022186282A1 (cg-RX-API-DMAC7.html) 2022-09-09
JPWO2022186282A5 true JPWO2022186282A5 (cg-RX-API-DMAC7.html) 2024-02-08

Family

ID=83154306

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023503916A Pending JPWO2022186282A1 (cg-RX-API-DMAC7.html) 2021-03-03 2022-03-02

Country Status (12)

Country Link
US (1) US20240173381A1 (cg-RX-API-DMAC7.html)
EP (1) EP4302785A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2022186282A1 (cg-RX-API-DMAC7.html)
KR (1) KR20240004273A (cg-RX-API-DMAC7.html)
AU (1) AU2022230492A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023017808A2 (cg-RX-API-DMAC7.html)
CA (1) CA3212726A1 (cg-RX-API-DMAC7.html)
IL (1) IL305627A (cg-RX-API-DMAC7.html)
MX (1) MX2023010315A (cg-RX-API-DMAC7.html)
PH (1) PH12023552425A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022186282A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202309227B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106542B (zh) 2014-10-20 2020-05-08 奥伊斯特普安生物制药公司 治疗眼部病状的方法
JP7868817B2 (ja) * 2024-04-02 2026-06-02 国立大学法人 鹿児島大学 糖尿病に対するsHB-EGF強化治療

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4839476B2 (ja) * 2005-09-28 2011-12-21 国立大学法人 鹿児島大学 ヘパリン結合性上皮増殖因子様増殖因子の新規医薬用途
JP2007223939A (ja) * 2006-02-22 2007-09-06 Kobe Univ エネルギー代謝促進因子としてのhb−egfの使用
JP5174022B2 (ja) * 2007-07-20 2013-04-03 学校法人 埼玉医科大学 膵臓β細胞増加促進剤及び膵臓β細胞増加促進組成物
JP6711495B1 (ja) 2019-05-27 2020-06-17 株式会社ナイスリー 車両用盗難防止装置
JP2021033714A (ja) 2019-08-26 2021-03-01 東芝テック株式会社 商品販売データ処理装置及びプログラム
JP7040807B2 (ja) 2020-03-17 2022-03-23 株式会社オリンピア 遊技機

Similar Documents

Publication Publication Date Title
US12409236B2 (en) Liver-specific nucleic acid regulatory elements and methods and use thereof
US20080254109A1 (en) Localized myocardial injection method for treating ischemic myocardium
US20040161412A1 (en) Cell-based VEGF delivery
Bai et al. Polyethylene glycol-modified pigment epithelial-derived factor: new prospects for treatment of retinal neovascularization
JP2004506658A5 (cg-RX-API-DMAC7.html)
JP2023517934A5 (cg-RX-API-DMAC7.html)
US20180296641A1 (en) Method to induce neovascular formation and tissue regeneration
Setoguchi et al. Stimulation of erythropoiesis by in vivo gene therapy: physiologic consequences of transfer of the human erythropoietin gene to experimental animals using an adenovirus vector
JP2023539626A5 (cg-RX-API-DMAC7.html)
US20030100889A1 (en) Method of administration of a gene of interest to a vascular tissue
EP2142206A1 (en) Method of treating ischemic disorders
JP2021533801A5 (cg-RX-API-DMAC7.html)
JP2006518595A (ja) インビボでの持続性が増加したアデノウイルスベクターを用いる方法
JP4124565B2 (ja) インターフェロンβのような分泌タンパク質をコードする遺伝子を使用する治療のための方法および組成物
JPWO2022107853A5 (cg-RX-API-DMAC7.html)
IL305627A (en) Hb-egf gene therapy for diabetes
JPWO2025211357A5 (cg-RX-API-DMAC7.html)
Hirsch et al. Gene therapy in cutaneous wound healing
KR20190082134A (ko) 유전자 전달용 세포 시트
US20230414718A1 (en) Low-dose hepatocyte growth factor gene therapy for diabetes
Suzuki et al. Pharmacological expression in rat hepatocytes of a gene transferred by an adenovirus vector enabled by a chimeric promoter containing multiple cyclic adenosine monophosphate response elements
Shen et al. Gene Therapy for Stroke
US20210269508A1 (en) Methods for regulating endogenous production of lactoferrin and sub-peptides thereof
Cyclohydrolase et al. 1111. Prolonged T 1. Prolonged T 1. Prolonged Transgene Expression in the ransgene Expression in the ransgene Expression in the Arterial Wall Using a Helper-Dependent all Using a Helper-Dependent all Using a Helper-Dependent Adenoviral V Adenoviral V Adenoviral Vector
CN116685340A (zh) 针对糖尿病的低剂量的肝细胞生长因子基因治疗